Nuvectis Pharma Licenses Exclusive Global Rights to New SRC / YES1 Inhibitor (NXP900) from University of Edinburgh, Scotland | No more news


Nuvectis Pharma In-Licenses the exclusive worldwide rights to a new SRC / YES1 inhibitor (NXP900) from the University of Edinburgh, Scotland

NXP900 is an SRC / YES1 kinase inhibitor with a new and differentiated mechanism of action.

FORT LEE, NJ, United States I September 14, 2021 I Nuvectis Pharma, Inc., a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions requiring an unmet medical need in oncology, today announced that it has licensed the exclusive worldwide rights to develop and commercialize a new oral small molecule. , SRC / YES1 inhibitor from the University of Edinburgh in Scotland. The compound, which has been designated NXP900, was discovered at Cancer Research UK Edinburgh Center of the University of Edinburgh’s Institute of Genetics and Cancer and is expected to begin studies allowing IND in 4T2021.

The pro-oncogenic effects of CRS kinase-mediated signaling in various types of solid tumors, including breast, colon, prostate, pancreatic and ovarian cancers are well documented. In addition, amplification of the YES1 gene has also been reported in various solid tumors including lung, head and neck, esophagus and sarcoma, and has also been described as a mechanism of acquired resistance to treatment. with inhibitors of EGFR which grows in a substantial percentage. patients with EGFR-mutated pulmonary adenocarcinomas.

NXP900 has a unique mechanism of action in that it inhibits both the catalytic and scaffolding functions of the SRC kinase, resulting in complete shutdown of the signaling pathway, unlike current multi-kinase inhibitors. approved and under development that target CRS but only inhibit its catalytic function. We believe that another key differentiator is that NXP900 does not inhibit ABL kinase, with in vivo data not indicating any treatment-related immunosuppression, a potential benefit in solid tumors. In vitro, NXP900 inhibited the activity of SRC and YES1 kinases at sub-nanomolar concentrations. In vivo, treatment with NXP900 inhibited primary and metastatic tumor growth in breast cancer xenograft models and demonstrated targeted pharmacodynamic effects. Data supporting the unique mechanism of action of NXP900 were recently published in the journal Cancer Research (“New mode of CRS inhibition improves drug efficacy and safety”, 10.1158 / 0008-5472.CAN-21 -0613). Together, we believe that NXP900 has the potential to become the first SRC / YES1 inhibitor for the treatment of solid tumors.

Neil Carragher, Professor of Drug Discovery and Director of Translation at the University of Edinburgh, said: “We believe that the selectivity and demonstrated potency of NXP900 in several animal models of cancer potentially offers a wide range of options. development, both as a single agent and in combination with approved drugs. We are excited to be working with Nuvectis to move NXP900 rapidly to IND studies, with the hope of starting clinical trials for NXP900 soon after.

Asier Unciti-Broceta, Professor of Medicinal Chemistry and Head of the Advanced Therapy Laboratory at the University of Edinburgh, said: “We are delighted to have partnered NXP900 with Nuvectis as a result of the Discovery Program at Institute of Genetics and Cancer. We are confident that Nuvectis’ skills and expertise in drug development bode well for the successful and rapid development of the NXP900 and ultimately hope that it will become a much needed new option that will benefit cancer patients. induced by SRC / YES1.

“We are delighted to partner with the Institute of Genetics and Cancer at the University of Edinburgh to advance the development of NXP900, which has demonstrated exceptional preclinical activity to date. We also thank Edinburgh Innovations, the university’s marketing department, for facilitating this license, ”said Ron Bentsur, co-founder, chairman and CEO of Nuvectis, who added:“ We believe that with our two products in pipeline, we are now one step closer to building a diverse business focused on precision medicine and oncology with the goal of helping more people in their fight against hard-to-treat cancers.

About Nuvectis Pharma

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision drugs for severe conditions of unmet medical need in oncology. Nuvectis was founded in 2020 and is led by a team of industry veterans with extensive and extensive experience in drug development and a proven track record of clinical and regulatory success. Nuvectis recently announced the completion of a $ 15 million Series A preferred share financing with institutional and private investors, as well as the granting of exclusive global licenses for NXP800, an oral small-molecule inhibitor of the pathway. HSF1 from the Institute of Cancer Research (ICR). A Phase 1 trial of NXP800 in patients with advanced solid tumors is expected to begin in 4Q2021. Nuvectis is also developing NXP900, an SRC / YES1 inhibitor, which should begin studies allowing IND to 4T2021.

For more information, please visit

About the University of Edinburgh

The University of Edinburgh is consistently ranked among the top 50 universities in the world and ranks 16th in the 2022 QS World University Rankings. Through its research, expertise, facilities and advanced technologies, the University of Edinburgh works closely with industry, business and government partners to develop innovative ideas in products, processes and services. that have a positive impact on society and the economy nationally and globally.

For more information, visit

About Edinburgh Innovations

Edinburgh Innovations is the marketing department of the University of Edinburgh. EI leads the University’s activities in industry engagement and business development, business support for students and staff, and the identification, management and commercialization of academic intellectual property. .

THE SOURCE: Nuvectis Pharma

Leave A Reply

Your email address will not be published.